Progress in the mechanism and drug development of castration-resistant prostate cancer.

Zuo, Minzan; Xu, Xi; Li, Tinghan; Ge, Raoling; Li, Zhiyu

Zuo, Minzan; Xu, Xi; Li, Tinghan; Ge, Raoling; Li, Zhiyu.

Affiliation

Zuo M; Department of Medicinal Chemistry, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing 210009, PR China.
Xu X; Department of Medicinal Chemistry, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing 210009, PR China.
Li T; Department of Medicinal Chemistry, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing 210009, PR China.
Ge R; Department of Medicinal Chemistry, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing 210009, PR China.
Li Z; Department of Medicinal Chemistry, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing 210009, PR China.

Future Med Chem ; 8(7): 765-88, 2016 05.

Article de En | MEDLINE | ID: mdl-27149562

Sujet(s)
Mots clés

androgen receptor antagonists; castration-resistant prostate cancer; cross-resistance; predictive biomarkers; prostate-specific antigen; treatment strategies

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Radiopharmaceutiques / Tumeurs prostatiques résistantes à la castration / Antinéoplasiques Type d'étude: Prognostic_studies Limites: Humans / Male Langue: En Journal: Future Med Chem Année: 2016 Type de document: Article

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google